The purpose of the present study was to examine the regulation of tumor necrosis factor α (TNFα) and interleukin (IL)-6 by lipopolysaccharide (LPS) in C2C12 myoblasts and mouse skeletal muscle. LPS produced dose-and time-dependent increases in TNFα and IL-6 mRNA content in C2C12 myoblasts. The LPS-induced cytokine response could be mimicked by peptidoglycan from the cell wall of Staphylococcus aureus but not by zymosan A, a cell wall component from Saccharomyces cerevisiae. Ongoing protein synthesis was not necessary for the increase in the two cytokine mRNAs. The transcriptional inhibitor DRB blocked LPS-stimulated IL-6 mRNA expression without changing its mRNA half-life. The anti-inflammatory glucocorticoid dexamethasone selectively blocked LPS-stimulated IL-6 mRNA accumulation, but not TNFα. In contrast, the proteasomal inhibitor MG132 blocked TNFα mRNA expression, but not IL-6. Exposure of myoblasts to LPS was associated with a rapid decrease in the inhibitor of nuclear factor kappa B (I kappa B α, and ε) and this response was also blocked by MG132. Treatment of myocytes with IL-1 or TNFa also increased IL-6 mRNA content, but the increase in IL-6 mRNA due to LPS could not be prevented by pretreatment with antagonists to either IL-1 or TNF. Under in vivo conditions, LPS increased the plasma concentration of TNFα and IL-6 and stimulated the accumulation of their mRNAs in multiple tissues including skeletal muscle from wild-type mice. In contrast, the ability of LPS to stimulate the same cytokines was markedly decreased in mice that harbor a mutation in the toll-like receptor 4. Our data suggest that LPS stimulates cytokine expression not only in classical immune tissues, but also in skeletal muscle.
INTRODUCTION
Lipopolysaccharide (LPS) derived from the cell wall of Gram-negative bacteria mediates many of the inflammatory sequelae of infection. LPS binds to the plasma LPS binding protein and the complex associates with CD14 (1), heat shock proteins, and a variety of other proteins on the surface of immune cells (43) . The interaction of LPS with a Toll-like receptor (TLR)-4 is essential for transduction of the LPS signal and the subsequent induction of inflammatory cytokine gene expression (23) . Two strains of mice (C3H/HeJ and C57BL/10ScCr) that harbor a mutation in TLR4 fail to induce cytokine expression and are resistant to the lethal effects of LPS (3; 35) .
TLR4 is part of a larger family of receptors that recognize pathogen associated molecular patterns (PAMPS). In Drosophilae melanogaster the Toll protein recognizes the PAMPS of fungi.
Orthologues in mammals, such as TLR2 and TLR6, recognize PAMPS that are present on yeast and Gram-positive bacteria (31) . TLR9 mediates the immune response to bacterial DNA (20) . The mammalian TLR family presently consists of 10 members, and this repertoire of receptors provides the immune system with the ability to respond to a wide variety of pathogens.
During infection resident macrophages in the liver, spleen, and peripheral tissues are activated as part of the innate immune response and synthesize a variety of cytokines. Cytokines play an integrative role in the immune response and may adopt both inflammatory and antiinflammatory roles. Cytokines can function either locally in a paracrine or autocrine manner or at sites distant from their site of production in a manner comparable to the endocrine hormones. LPS is a strong inducer of many cytokines including tumor necrosis factor α (TNFα), and interleukin-6 (IL-6). Several lines of evidence indicate that these cytokines are important regulators of muscle protein balance. First, TNFα impairs muscle protein metabolism when administered to control animals (7; 15; 18; 27; 42) . Second, cytokine antagonists prevent or reverse sepsis-or LPS-induced changes in muscle protein synthesis (7; 24) . Finally, proinflammatory cytokines decrease circulating and tissue levels of important anabolic hormones, such as insulin-like growth factor-I (IGF-I), that would be expected to further impair muscle protein balance (12; 13) .
LPS stimulates cytokine mRNA and protein expression in classical immune tissues such as the liver, spleen, and lung, as well as non-immune tissues such as cardiac muscle (8; 16) . The cell types that contribute to this signal have not been fully delineated but potentially could include peripheral blood mononuclear cells, endothelial cells, myocytes and/or satellite cells. The current experiments were designed to test whether LPS plays a direct role in stimulating cytokine expression in skeletal muscle in vivo and C2C12 myoblasts in vitro. In addition, we have characterized the in vitro regulation of TNFα and IL-6 mRNA by LPS, dexamethasone, and MG132.
MATERIALS AND METHODS
Cell culture. The C2C12 mouse myoblast cell line was purchased from the American Type Culture Collection (ATCC, Manassas, MD) and used for all studies. Cells were grown in 100 mm Petri dishes (Becton Dickinson, Franklin Lakes, NJ) and cultured in minimal essential media (MEM) containing 5% newborn calf serum, penicillin (100 U/ml), streptomycin (100 µg/ml) and amphotericin B (25 µg/ml) (all from Sigma, St. Louis, MO). Cells were grown to confluence and switched to fresh serum-containing media prior to addition of LPS, cytokines, or other agents. C2C12 cells were used at the myoblast stage. We and Alvarez et al (2) Conditioned media was diluted with an equal volume of assay diluent whereas plasma was diluted 1:12 prior to assay. Antigen and antibody complexes were detected with tetramethylbenzidine (TMB, an HRP substrate) and the reaction stopped with 2 N H 2 SO 4 . Ninety-six well plates were read at the absorption maximum for TMB (450 nm). TNFα in mouse plasma was measured as described above with the exception that an anti-mouse TNFα polyclonal antibody and monoclonal antibody were used as the capture and detection antibodies, respectively (Pharminigen).
Experimental protocol for C3H/HeJ and C3H/HeSnJ mice. C3H/HeJ and C3H/HeSnJ mice were obtained from the Jackson Laboratories (Bar Harbor, ME). All mice were housed in a controlled environment and provided water and rodent chow ad libitum for 3 weeks prior to their use.
At the time of the study mice were 8-9 weeks old and weighed 21.4± 0.3 g. In the experiment depicted in Figure 1 wild-type C3H/HeSnJ mice were injected intraperitoneally with LPS derived from E. coli 026:B6 (DIFCO, 25 µg per mouse) or an equal volume of saline, 250 µl/mouse). This dose was based on a preliminary dose response in C3H/HeSnJ mice and is similar to that used by other investigators (4). After 2 h mice were anesthetized with a mixture of ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (Bayer, Shawnee Mission, KS) and blood collected from the inferior vena cava in heparinized syringes. Individual tissues were wrapped in aluminum foil and flash frozen in liquid nitrogen. Tissues were later powdered under liquid nitrogen using a mortar and pestle and stored at -70 o C. For the experiment depicted in Figure 11 , mice were separated into 4 experimental groups: C3H/HeSnJ mice that received saline (WT/Sal), C3H/HeSnJ mice that were injected with LPS (WT/ LPS), C3H/HeJ mice that received saline (HeJ/ Sal) and C3H/HeJ mice that were injected with LPS (HeJ/LPS). Mice were injected intraperitoneally with LPS or saline as described above. After 2 h mice were anesthetized with a mixture of ketamine and xylazine and blood and tissues collected as described above. All experiments were approved by the Animal Care (two control groups) and 6 (two LPS treated groups). Cytokine mRNAs are differentially regulated at the transcriptional and translational level in C2C12 myoblasts. LPS is known to affect cytokine expression at multiple levels including transcription (26) , translation (36), processing, and secretion (30) . We examined whether ongoing protein synthesis was necessary for LPS to stimulate TNFα and IL-6 mRNA expression.
RESULTS

LPS increases
Cycloheximide did not blunt the LPS-induced increase in either TNFα or IL-6 mRNA content.
Cycloheximide increased basal IL-6 mRNA content on its own and acted synergistically with LPS to and are hypo-responsive to LPS (46) . These mice and a comparable wild-type strain were used to determine whether administration of LPS increased cytokine mRNA content in skeletal muscle in vivo and whether the TLR4 receptor is necessary for such stimulation. C3H/HeJ and wild-type mice (C3H/ HeSnJ) were injected with a non-lethal dose of LPS and blood and tissue samples obtained near the peak of cytokine expression (2 h). LPS increased the plasma concentration of TNFα (17-fold) and IL-6 (14-fold) as determined by ELISA (Table 2 ). This response was severely blunted in C3H/HeJ mice (TNFα, 2% of wild-type and IL-6, 11% of wild-type). The cytokine expression pattern in skeletal muscle in response to LPS was similar to that seen with C2C12 cells consisting of a large increase in IL-6 (107-fold), and TNFα (9-fold) mRNA ( Figure 11 , Panel C, and Table 2 ). LPS also stimulated IL-6 mRNA expression in the spleen, liver, and heart of wild-type mice ( Figure 11 , Panels A-D). C3H/HeJ mice were hypo-responsive to LPS in multiple tissues including the spleen (30%), the liver (0%), the gastrocnemius (4%), and the heart (3%) when the level of IL-6 mRNA content was compared with wild-type mice. C3H/HeJ mice were also hypo-responsive to LPS at the level of TNFα mRNA in skeletal muscle (Table 2) . Cardiac muscle from C3H/HeJ mice was hyporesponsive to LPS at the level of IL-6 (3%) compared with control mice (Table 2 ). In contrast, C3H/HeJ mice were surprisingly responsive to LPS at the level of TNFα mRNA expression in cardiac muscle with a response that achieved 72% of that seen in wild-type mice. Cardiac IL-6 mRNA was elevated in the basal state of C3H/HeJ mice when compared to wild-type mice ( Table 2) .
DISCUSSION
This study demonstrates that LPS stimulates the expression of cytokines in both skeletal muscle in vivo and C2C12 myoblasts in vitro. Although LPS is known to increase cytokine expression in immune cells less is understood about its effect on skeletal muscle or muscle cells. Critical illness is often associated with a loss of muscle protein due to both increased muscle proteolysis and a decrease in muscle protein synthesis (6) . Amino acids are mobilized from skeletal muscle and reutilized by other tissues, such as the liver, for the synthesis of acute phase proteins (21) . Although the response to infection is often viewed as a systemic event, local synthesis of proinflammatory cytokines in skeletal muscle may also promote muscle wasting. TNFα inhibits protein synthesis in human skeletal muscle cells in vitro (17) and rat skeletal muscle in vivo (25) . IL-6 also enhances protein degradation in C2C12 myoblasts (11) and dramatically stunts growth in transgenic mice that over express the protein (10) . Conversely, local expression of antiinflammatory cytokines such as IL-1Ra may limit the loss of muscle protein. Systemic infusion of an IL-1Ra prevents the decrease in skeletal muscle protein synthesis that occurs in a rat model of sepsis (24) . IL-12 also prevents deterioration of diaphragmatic muscle function in septic rats (32) .
In general, the cytokine response of C3H/HeJ mice to LPS was greatly reduced when myoblasts. C2C12 cells were grown as described in Figure 2 and treated with 0.01, 0.1, 1.0 or 10 µg/ml of E. coli LPS for either 1h (TNFα) or 4h (IL-6). RNA was isolated and hybridized to a cytokine mRNA ribonuclease protection assay template as described in the Methods and run on a 5% acrylamide gel. The dried gel was exposed to a phosphor imager screen and quantified with ImageQuant TM software. All data are normalized to L32 mRNA as described in the Methods. IL-12  100  125  69  138  919  2147  1566  599  IL-1α  100  125  122  220  132  126  93  61  IL-1 Ra  100  105  90  110  153  402  470  48  IL-18  100  118  102  112  109  86  66  40  TNFβ  100  163  102  173  157  137  147  150  TGFβ1  100  100  110  119  173  168  126  74  TGFβ2  100  92  88  91  83  52  39  25  TGFβ3  100  102  103  94  79  47  42  27 Values are expressed as a percentage of control cells not treated with LPS. 
